Wright Medical Group Acquires Cartiva, Inc.

Client Type: Public Company

We served as lead counsel to Wright Medical Group N.V. (Nasdaq: WMGI) in the acquisition of Cartiva, Inc., a privately-held orthopaedic medical device company dedicated to improving the quality of life of patients with osteoarthritis, cartilage damage and other musculoskeletal conditions, for $435 million. Cartiva focuses on treatment of osteoarthritis of the great toe. The transaction was completed in October 2018.

JP Morgan Securities, LLC served as financial advisor on the transaction

Wright Medical Group N.V. is a global medical device company focused on extremities and biologics products. The company is committed to delivering innovative, value-added solutions improving the quality of life for patients worldwide. Wright is a recognized leader of surgical solutions for the upper extremities (shoulder, elbow, wrist and hand), lower extremities (foot and ankle) and biologics markets, three of the fastest growing segments in orthopaedics.

This transaction was named a finalist in the “Corporate/Strategic Deal of the Year ($250MM-$500MM)” category for the 18th Annual M&A Advisor Awards in 2019. Bass, Berry & Sims had six separate deals recognized as finalists among nine categories for the 2019 M&A Advisor Awards.

We served as lead counsel to Wright Medical Group N.V. (Nasdaq: WMGI) in the acquisition of Cartiva, Inc., a privately-held orthopaedic medical device company dedicated to improving the quality of life of patients with osteoarthritis, cartilage damage and other musculoskeletal conditions, for $435 million. Cartiva focuses on treatment of osteoarthritis of the great toe. The transaction was completed in October 2018.

JP Morgan Securities, LLC served as financial advisor on the transaction

Wright Medical Group N.V. is a global medical device company focused on extremities and biologics products. The company is committed to delivering innovative, value-added solutions improving the quality of life for patients worldwide. Wright is a recognized leader of surgical solutions for the upper extremities (shoulder, elbow, wrist and hand), lower extremities (foot and ankle) and biologics markets, three of the fastest growing segments in orthopaedics.

This transaction was named a finalist in the “Corporate/Strategic Deal of the Year ($250MM-$500MM)” category for the 18th Annual M&A Advisor Awards in 2019. Bass, Berry & Sims had six separate deals recognized as finalists among nine categories for the 2019 M&A Advisor Awards.